TW260708B - - Google Patents

Info

Publication number
TW260708B
TW260708B TW082110255A TW82110255A TW260708B TW 260708 B TW260708 B TW 260708B TW 082110255 A TW082110255 A TW 082110255A TW 82110255 A TW82110255 A TW 82110255A TW 260708 B TW260708 B TW 260708B
Authority
TW
Taiwan
Prior art keywords
encapsidation
aav
replication
dna fragments
patients suffering
Prior art date
Application number
TW082110255A
Other languages
English (en)
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Application granted granted Critical
Publication of TW260708B publication Critical patent/TW260708B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW082110255A 1992-12-04 1993-12-04 TW260708B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/989,841 US5478745A (en) 1992-12-04 1992-12-04 Recombinant viral vector system

Publications (1)

Publication Number Publication Date
TW260708B true TW260708B (zh) 1995-10-21

Family

ID=25535518

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082110255A TW260708B (zh) 1992-12-04 1993-12-04

Country Status (9)

Country Link
US (1) US5478745A (zh)
EP (1) EP0673415B1 (zh)
JP (1) JP4117023B2 (zh)
KR (1) KR100256890B1 (zh)
AT (1) ATE423203T1 (zh)
DE (1) DE69334262D1 (zh)
IL (1) IL107862A0 (zh)
TW (1) TW260708B (zh)
WO (1) WO1994013788A1 (zh)

Families Citing this family (438)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736367A (en) * 1992-03-31 1998-04-07 Medimmune, Inc. Vectors and prokaryotes which autocatalytically delete antibiotic resistance
US5869305A (en) * 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US5693531A (en) * 1993-11-24 1997-12-02 The United States Of America As Represented By The Department Of Health And Human Services Vector systems for the generation of adeno-associated virus particles
EP0755454B1 (en) 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
JPH10511264A (ja) * 1994-12-06 1998-11-04 ターゲティッド ジェネティックス コーポレイション 高力価組換えａａｖベクターの生成のためのパッケージング細胞株
US6924128B2 (en) 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
ATE452981T1 (de) * 1995-06-07 2010-01-15 Univ North Carolina Die transduktion von myoblasten mittels vektoren aus adenoassoziierten viren
IL122349A0 (en) * 1995-06-07 1998-04-05 Univ Yale Adeno-associated viral vectors
US6093570A (en) * 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
AU763063B2 (en) * 1995-06-07 2003-07-10 University Of North Carolina At Chapel Hill, The AAV transduction of myoblasts
US6040183A (en) * 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6110456A (en) * 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US6248720B1 (en) 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
JPH11510142A (ja) 1995-07-21 1999-09-07 ブラウン・ユニバーシティ・リサーチ・ファンデーション 核酸負荷ポリマー微粒子を使用した遺伝子治療法
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6207457B1 (en) 1995-09-08 2001-03-27 Avigen, Inc. Targeted nucleotide sequence delivery and integration system
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
US5846528A (en) * 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5962313A (en) 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
US5858351A (en) * 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
DE19608753C1 (de) * 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
EP0927044A4 (en) * 1996-04-16 1999-09-08 Immusol Inc DEFINED TARGET VIRAL VECTORS
EP0933997A4 (en) * 1996-09-06 2000-08-16 Chiron Corp METHODS AND COMPOSITIONS FOR LIVER-SPECIFIC ADMINISTRATION OF THERAPEUTIC MOLECULES USING RECOMBINANT AAV VECTORS
US20020037867A1 (en) * 1999-02-26 2002-03-28 James M. Wilson Method for recombinant adeno-associated virus-directed gene therapy
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
IL128780A0 (en) * 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
AU741605B2 (en) 1996-12-18 2001-12-06 Targeted Genetics Corporation AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
EP0856585A1 (en) 1997-01-29 1998-08-05 Introgene B.V. A conditional replication and expression system
US6037177A (en) * 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2830694C (en) 1997-09-05 2018-02-27 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
AU1269699A (en) * 1997-10-08 1999-04-27 Advanced Research And Technology Institute, Inc. Chimeric parvovirus-based recombinant vector system that specifically targets the erythroid lineage
US6642051B1 (en) 1997-10-21 2003-11-04 Targeted Genetics Corporation Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
WO1999024578A2 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
DE69943022D1 (de) 1998-03-19 2011-01-20 Human Genome Sciences Rockville Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
WO2001031019A2 (en) 1999-10-29 2001-05-03 Chiron Spa Neisserial antigenic peptides
EP2261339B1 (en) 1998-05-01 2017-03-22 GlaxoSmithKline Biologicals SA Neisseria meningitidis antigens and compositions
US6436392B1 (en) 1998-05-20 2002-08-20 University Of Iowa Research Foundation Adeno-associated virus vectors
EP1849872A1 (en) * 1998-05-20 2007-10-31 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
EP1930418B1 (en) 1998-09-04 2015-04-08 Genzyme Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6491907B1 (en) * 1998-11-10 2002-12-10 The University Of North Carolina At Chapel Hill Recombinant parvovirus vectors and method of making
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US20040043488A1 (en) * 1999-02-17 2004-03-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Adeno-associated viral gene-transfer vector system
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
EP1939300A1 (en) 1999-05-28 2008-07-02 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
WO2000073481A1 (en) 1999-05-28 2000-12-07 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (tnf) in the tnf-associated disorders
JP4969002B2 (ja) 1999-06-08 2012-07-04 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン ｒＡＡＶ形質導入を増加するための化合物および方法
US7122335B1 (en) 1999-06-08 2006-10-17 University Of Iowa Research Foundation Compounds and methods to enhance rAAV transduction
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP1916258B1 (en) 1999-08-09 2014-04-23 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
DK1916258T3 (da) * 1999-08-09 2014-07-28 Genzyme Corp Forøgelse af ekspression af en enkeltstrenget, heterolog nukleotidsekvens fra rekombinante, virale vektorer ved en sådan udformning af sekvensen at den danner intrastrengbasepar
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
WO2001029243A1 (en) 1999-10-15 2001-04-26 Dalhousie University Method and vector for producing and transferring trans-spliced peptides
PT1248647E (pt) 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
US6429001B1 (en) 2000-01-26 2002-08-06 Chiron Corporation Recombinant AAV packaging systems
JP2003530847A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
EP2277894A1 (en) 2000-10-27 2011-01-26 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A & B
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
US8067156B2 (en) * 2001-05-31 2011-11-29 The Rockefeller University Method for generating replication defective viral vectors that are helper free
US8241622B2 (en) 2001-07-13 2012-08-14 University Of Iowa Research Foundation Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
WO2003013683A1 (en) * 2001-08-08 2003-02-20 Brown University Research Foundation Methods for micronization of hydrophobic drugs
WO2003035687A1 (en) * 2001-10-22 2003-05-01 Novartis Ag Nogo receptor homologues and their use
CA2406745C (en) 2001-11-13 2006-01-10 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
US20030147965A1 (en) * 2001-12-10 2003-08-07 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
JP4413617B2 (ja) 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化
FI3517134T3 (fi) 2001-12-17 2024-04-03 Univ Pennsylvania Adeno-assosioituneen viruksen (aav) serotyypin 8 sekvenssejä, niitä sisältäviä vektoreita ja niiden käyttöjä
EP3339430A1 (en) 2001-12-17 2018-06-27 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses thereof
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003087367A2 (en) 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1562970A4 (en) 2002-11-01 2006-04-12 Univ Pennsylvania COMPOSITIONS AND METHODS FOR INHIBITING HIF-1 ALPHA WITH ARNS
WO2004043387A2 (en) 2002-11-13 2004-05-27 Thomas Jefferson University Compositions and methods for cancer diagnosis and therapy
JP2007524349A (ja) 2003-01-16 2007-08-30 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ＩＣＡＭ−１のｓｉＲＮＡ阻害のための組成物及び方法
WO2004065551A2 (en) * 2003-01-21 2004-08-05 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (mgat3), and uses thereof
CA2520016A1 (en) 2003-03-31 2004-10-21 University Of Iowa Research Foundation Pharmico-gene therapy of epithelial sodium channel associated disorders
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US20050019927A1 (en) * 2003-07-13 2005-01-27 Markus Hildinger DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
EP3211085B1 (en) 2003-09-30 2021-03-31 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
CA2554818A1 (en) 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
ES2423060T3 (es) 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
CN1957082B (zh) 2004-03-29 2014-09-17 株式会社嘉尔药物 新的半乳凝素9突变体蛋白质及其用途
WO2006012625A2 (en) * 2004-07-22 2006-02-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Stat3 decoy oligonucleotides and uses therefor
EP1828390B1 (en) * 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
EP2357010B1 (en) 2005-04-07 2013-06-12 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
EP2796554A3 (en) 2005-09-12 2014-12-10 The Ohio State University Research Foundation Compositions for use in treating BCL2-associated cancers
CA2634286A1 (en) 2005-12-22 2007-08-09 Samuel Jotham Reich Compositions and methods for regulating complement system
WO2007081720A2 (en) 2006-01-05 2007-07-19 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
CN101384273B (zh) 2006-01-05 2013-07-10 俄亥俄州立大学研究基金会 胰腺内分泌和腺泡肿瘤中的微小rna表达异常
EP2487263B1 (en) 2006-01-05 2014-03-19 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers of the pancreas
EP1981548A4 (en) * 2006-01-20 2010-03-24 Univ North Carolina ENHANCED PRODUCTION OF INFECTIOUS VECTORS OF PARVOVIRUS IN INSECT CELLS
EP2522750A1 (en) 2006-03-02 2012-11-14 The Ohio State University MicroRNA expression profile associated with pancreatic cancer
CA2647769C (en) 2006-03-20 2015-05-26 Japan Science And Technology Agency Control of intracellular target molecule by ip3 receptor-binding protein
ES2446362T3 (es) 2006-03-20 2014-03-07 The Ohio State University Research Foundation Huellas de microARN durante megacariocipoyesis humana
WO2007115168A2 (en) 2006-03-31 2007-10-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 gene
US7691824B2 (en) 2006-04-28 2010-04-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the JC virus
EP2584048B1 (en) 2006-05-11 2014-07-23 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
BRPI0712034A2 (pt) 2006-05-19 2012-01-10 Alnylam Pharmaceuticals Inc modulação de rnai de aha e usos terapêuticos do mesmo
AU2007253677B2 (en) 2006-05-22 2011-02-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of IKK-B gene
US8598333B2 (en) 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
ES2390499T3 (es) 2006-06-12 2012-11-13 Opko Pharmaceuticals, Llc Composiciones y métodos para la inhibición de la angiogénesis por sirna
ES2535877T3 (es) 2006-06-19 2015-05-18 Asklepios Biopharmaceutical, Inc. Genes de Factor VIII y Factor IX modificados y vectores para la terapia génica
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2455493B1 (en) 2006-07-13 2014-01-08 The Ohio State University Research Foundation Micro-RNA-based methods and compositions for the diagnosis and treatment of colon related diseases
PL2044199T3 (pl) * 2006-07-25 2013-04-30 Celladon Corp Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej
US7872118B2 (en) 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
CA2663581C (en) 2006-09-21 2016-03-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the hamp gene
US8841436B2 (en) 2007-03-15 2014-09-23 University Hospitals Cleveland Medical Center Screening, diagnosing, treating and prognosis of pathophysiologic status by RNA regulation
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
AP3018A (en) 2007-03-29 2014-10-31 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expressionof a gene from the ebola
US20100184823A1 (en) 2007-07-05 2010-07-22 Mark Aron Labow dsRNA For Treating Viral Infection
WO2009012263A2 (en) 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
US8367632B2 (en) 2007-07-31 2013-02-05 Ohio State University Research Foundation Methods for reverting methylation by targeting methyltransferases
CN101835902B (zh) 2007-08-03 2014-03-26 俄亥俄州立大学研究基金会 编码ncrna的超保守区域
EP2183593B1 (en) 2007-08-22 2016-01-13 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
EP3048177A1 (en) 2007-09-06 2016-07-27 The Ohio State University Research Foundation Microrna signatures in human ovarian cancer
CN101861401B (zh) 2007-10-11 2014-03-12 俄亥俄州立大学研究基金会 用于诊断和治疗食管腺癌的方法和组合物
CA2707042A1 (en) 2007-12-10 2009-06-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor vii gene
EP2244740A1 (en) 2008-02-19 2010-11-03 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium
JP2011518117A (ja) 2008-03-05 2011-06-23 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｅｇ５およびＶＥＧＦ遺伝子の発現を阻害するための組成物および方法
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8318693B2 (en) 2008-09-02 2012-11-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mutant EGFR gene
JP5529142B2 (ja) 2008-09-25 2014-06-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド 血清アミロイドａ遺伝子の発現を阻害するための脂質製剤組成物および方法
DK2937418T3 (en) 2008-10-20 2018-01-22 Alnylam Pharmaceuticals Inc Compositions and Methods for Inhibiting Transthyretin Expression
KR20110094323A (ko) 2008-12-04 2011-08-23 옵코 옵탈믹스, 엘엘씨 향-혈관신생성 ｖｅｇｆ 이소형의 선택적 억제를 위한 조성물 및 방법
US8324368B2 (en) 2008-12-10 2012-12-04 Alnylam Pharmaceuticals, Inc. GNAQ targeted dsRNA compositions and methods for inhibiting expression
US8889641B2 (en) 2009-02-11 2014-11-18 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
US20100267806A1 (en) 2009-03-12 2010-10-21 David Bumcrot LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
CN102448501A (zh) 2009-03-27 2012-05-09 西马生物医学计划公司 治疗肝硬化和肝纤维化的方法和组合物
ES2724122T3 (es) 2009-04-30 2019-09-06 Univ Pennsylvania Composiciones para dirigir células de las vías respiratorias de conducción que comprenden construcciones de virus adenoasociado
HUE039345T2 (hu) 2009-05-02 2018-12-28 Genzyme Corp Génterápia neurodegeneratív rendellenességekre
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
EP2810643A3 (en) 2009-08-14 2015-03-11 Alnylam Pharmaceuticals Inc. Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus
US20120244127A1 (en) 2009-10-01 2012-09-27 The Trustees Of The University Of Pennsylvania AAV Vectors Expressing SEC10 for Treating Kidney Damage
ES2632431T3 (es) 2009-10-30 2017-09-13 Ntf Therapeutics, Inc. Moléculas de neurturina mejoradas
CN105031618A (zh) 2009-11-02 2015-11-11 加利福尼亚大学董事会 用于细胞因子递送的穹窿体复合物
RU2012123145A (ru) 2009-11-05 2013-12-10 Проекто Де Биомедисина Сима, С.Л. Генный конструкт (варианты), вектор и рекомбинантный вирусный геном на его основе, вирион, их фармацевтическая композиция, способ in vitro экспрессии полинуклеотида в клетке печеночной природы, лекарственное средство, способ лечения заболевания печени (варианты), индуцируемый двунаправленный оператор-промотор
US8551781B2 (en) 2009-11-19 2013-10-08 The Regents Of The University Of California Vault complexes for facilitating biomolecule delivery
WO2011069155A1 (en) 2009-12-04 2011-06-09 Opko Ophthalmics, Llc Compositions and methods for inhibition of vegf
WO2011084694A1 (en) 2009-12-17 2011-07-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Stabilized stat3 decoy oligonucleotides and uses therefor
US9169494B2 (en) 2010-01-12 2015-10-27 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
EP2552456B1 (en) 2010-03-29 2017-08-23 Alnylam Pharmaceuticals, Inc. Sirna therapy for transthyretin (ttr) related ocular amyloidosis
US9546369B2 (en) 2010-04-23 2017-01-17 University Of Massachusetts Multicistronic expression constructs
EP2826860B1 (en) 2010-04-23 2018-08-22 University of Massachusetts CNS targeting AAV vectors and methods of use thereof
EP2561078B1 (en) 2010-04-23 2018-09-19 Cold Spring Harbor Laboratory NOVEL STRUCTURALLY DESIGNED shRNAs
US9272053B2 (en) 2010-04-23 2016-03-01 University Of Massachusetts AAV-based treatment of cholesterol-related disorders
JP6081910B2 (ja) 2010-06-02 2017-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 肝線維症治療用組成物および肝線維症の治療法
AR084469A1 (es) 2010-07-09 2013-05-22 Exelixis Inc Combinaciones de inhibidores de quinasas para el tratamiento del cancer
CA2805170C (en) 2010-07-12 2021-09-21 Fatima Bosch Tubert Gene therapy composition for use in diabetes treatment
EP2426203B1 (en) 2010-09-02 2016-07-13 Université de Mons Agents useful in treating facioscapulohumeral muscular dystrophy
EP2649182A4 (en) 2010-12-10 2015-05-06 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHOD FOR INCREASING AN ERYTHROPOIETIN (EPO) PREPARATION
EP2648763A4 (en) 2010-12-10 2014-05-14 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
CN103502458B (zh) 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
CA3217805A1 (en) 2011-03-29 2012-10-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of tmprss6 gene
WO2012145509A2 (en) 2011-04-19 2012-10-26 The Research Foundation Of State University Of New York Adeno-associated-virus rep sequences, vectors, and viruses
EP3699286A1 (en) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
EP3318635A1 (en) 2011-04-21 2018-05-09 University of Massachusetts Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
US20140134728A1 (en) 2011-06-01 2014-05-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for adjusting expression of mitochondrial genome by microrna
JP2014526882A (ja) 2011-06-21 2014-10-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド 対象中の治療剤の活性を判定するアッセイおよび方法
EP3388068A1 (en) 2011-06-21 2018-10-17 Alnylam Pharmaceuticals, Inc. Composition and methods for inhibition of expression of protein c (proc) genes
KR20230084331A (ko) 2011-06-21 2023-06-12 알닐람 파마슈티칼스 인코포레이티드 아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
EP2723758B1 (en) 2011-06-21 2018-06-20 Alnylam Pharmaceuticals, Inc. Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
EP2723390B1 (en) 2011-06-23 2017-12-27 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
EP2739735A2 (en) 2011-08-01 2014-06-11 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
CA2852066A1 (en) 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
WO2013060894A1 (en) 2011-10-27 2013-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and diagnosis of atherosclerosis
KR20140123571A (ko) 2012-02-16 2014-10-22 에이티와이알 파마, 인코포레이티드 자가면역 및 염증성 질환의 치료를 위한 히스티딜­ｔｒｎａ 신테타제
US20150190532A1 (en) 2012-04-04 2015-07-09 The Trustees Of Columbia University In The City Of New York Smooth muscle specific inhibition for anti-restenotic therapy
US9193971B2 (en) 2012-04-10 2015-11-24 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for the treatment of nonalcoholic steatohepatitis
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
WO2013153139A1 (en) 2012-04-11 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and diagnosis of acute leukemia
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
US20150150821A1 (en) 2012-07-09 2015-06-04 The Regents Of The University Of California Vault Immunotherapy
NZ704275A (en) 2012-07-11 2016-09-30 Univ Florida Aav-mediated gene therapy for rpgr x-linked retinal degeneration
EP2692868A1 (en) 2012-08-02 2014-02-05 Universitat Autònoma De Barcelona Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
CN111621507A (zh) * 2012-09-28 2020-09-04 北卡罗来纳-查佩尔山大学 靶向少突胶质细胞的aav载体
MX367076B (es) 2012-12-05 2019-08-05 Alnylam Pharmaceuticals Inc Composiciones de arni de proteina convertasa subtilisina kexina 9 (pcsk9) y metodos de uso de las mismas.
WO2014120975A1 (en) 2013-02-01 2014-08-07 California Institute Of Technology Antibody-mediated immunocontraception
DK2954051T3 (da) 2013-02-08 2019-07-08 Univ Pennsylvania Modificeret kapsid til genoverførsel til behandling af nethinden
US8957044B2 (en) 2013-03-01 2015-02-17 Wake Forest University Health Sciences Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
DK2968424T3 (da) 2013-03-13 2020-03-30 Geneweave Biosciences Inc Ikke-replikative transduktionspartikler og transduktionspartikelbaserede reportersystemer
ES2649490T3 (es) 2013-03-14 2018-01-12 Alnylam Pharmaceuticals, Inc. Composiciones de ARNi contra el componente C5 del complemento y métodos para su uso
EP2968612B1 (en) 2013-03-14 2018-02-14 Asklepios Biopharmaceutical, Inc. Modified soluble vegf receptor-1 genes and vectors for gene therapy
CA2901328C (en) 2013-03-15 2023-08-01 The Trustees Of The University Of Pennsylvania Compositions and methods for treating mps1
WO2014160871A2 (en) 2013-03-27 2014-10-02 The General Hospital Corporation Methods and agents for treating alzheimer's disease
JP6516725B2 (ja) 2013-04-08 2019-05-22 ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン キメラアデノ随伴ウイルス／ボカウイルスパルボウイルスベクター
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
BR112015029276B1 (pt) 2013-05-22 2022-07-12 Alnylam Pharmaceuticals, Inc Agente de irna fita dupla capaz de inibir a expressão de tmprss6, composição farmacêutica e uso dos mesmos
SG10201804472YA (en) 2013-05-22 2018-07-30 Alnylam Pharmaceuticals Inc SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CA2913418C (en) 2013-05-29 2021-11-23 Vybion, Inc. Single chain intrabodies that alter huntingtin mutant degradation
CN105431451A (zh) 2013-06-24 2016-03-23 肖卫东 突变型因子viii组合物和方法
EP3068889B1 (en) 2013-09-26 2019-04-17 Universitat Autònoma De Barcelona Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
TWI669393B (zh) 2013-10-02 2019-08-21 艾爾妮蘭製藥公司 抑制ｌｅｃｔ２基因表現之組合物及方法
NZ757749A (en) 2013-10-04 2022-07-01 Icahn School Med Mount Sinai Compositions and methods for inhibiting expression of the alas1 gene
WO2015086828A1 (en) 2013-12-12 2015-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and treatment of diabetic cardiomyopathy using mir-424/322
IL282401B (en) 2013-12-12 2022-08-01 Alnylam Pharmaceuticals Inc Complementary component irna compositions and methods for using them
JP6594902B2 (ja) 2014-02-11 2019-10-23 アルナイラム ファーマシューティカルズ， インコーポレイテッド ケトヘキソキナーゼ（ＫＨＫ）ｉＲＮＡ組成物及びその使用方法
WO2015127128A2 (en) 2014-02-19 2015-08-27 University Of Massachusetts Recombinant aavs having useful transcytosis properties
DK3119797T3 (da) 2014-03-18 2021-03-15 Univ Massachusetts Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
CA2946392A1 (en) 2014-04-25 2015-10-29 James M. Wilson Ldlr variants and their use in compositions for reducing cholesterol levels
EP3134522B1 (en) 2014-04-25 2021-10-06 University of Massachusetts Recombinant aav vectors useful for reducing immunity against transgene products
TW201607559A (zh) 2014-05-12 2016-03-01 阿尼拉製藥公司 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
BR112016026950B1 (pt) 2014-05-22 2023-03-07 Alnylam Pharmaceuticals, Inc Agente de ácido ribonucleico (rnai) de fita dupla, seus usos e composição farmacêutica
WO2015187825A2 (en) 2014-06-03 2015-12-10 University Of Massachusetts Compositions and methods for modulating dysferlin expression
US9458464B2 (en) 2014-06-23 2016-10-04 The Johns Hopkins University Treatment of neuropathic pain
JP2017525377A (ja) 2014-08-25 2017-09-07 ジーンウィーブ バイオサイエンシズ，インコーポレイティド 非複製的形質導入粒子及び形質導入粒子に基づくレポーターシステム
CA2957802A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
WO2016037931A1 (en) 2014-09-11 2016-03-17 Fundación Para La Investigación Médica Aplicada Nucleic acid constructs and expression vectors for gene therapy of acute porphyrias and other diseases
JP6842410B2 (ja) 2014-10-03 2021-03-17 ユニバーシティ オブ マサチューセッツ 新規の高効率ライブラリーにより同定されるａａｖベクター
WO2016054554A1 (en) 2014-10-03 2016-04-07 University Of Massachusetts Heterologous targeting peptide grafted aavs
JOP20200115A1 (ar) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
EP3221451A1 (en) 2014-11-17 2017-09-27 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
RU2727015C2 (ru) 2014-11-21 2020-07-17 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Векторы aav, нацеленные на центральную нервную систему
CA2967468A1 (en) 2014-12-16 2016-06-23 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease
EP3242945B1 (en) 2015-01-07 2021-09-01 Universitat Autònoma de Barcelona Single-vector gene construct comprising insulin and glucokinase genes
AU2016206624B2 (en) 2015-01-14 2020-08-06 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
CN107531774B (zh) 2015-02-06 2021-12-14 北卡罗来纳大学查珀尔希尔分校 优化的人类凝血因子viii基因表达盒及其用途
US10584321B2 (en) 2015-02-13 2020-03-10 University Of Massachusetts Compositions and methods for transient delivery of nucleases
WO2016130806A2 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
DK3268024T3 (da) 2015-03-10 2020-12-07 Univ Columbia Rekombinante glut1-adeno-associerede virusvektorkonstrukter og relaterede fremgangsmåder til genoprettelse af glut1-ekspression
US11046955B2 (en) 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
EP3307310A2 (en) 2015-05-13 2018-04-18 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-influenza antibodies and methods of use thereof
EP3294309A4 (en) 2015-05-14 2019-01-16 St. Jude Children's Research Hospital, Inc. NUCLEIC ACID MOLECULES WITH SPACERS AND METHOD FOR USE THEREOF
EP4000631A1 (en) 2015-05-15 2022-05-25 REGENXBIO Inc. Adeno-associated for therapeutic delivery to central nervous system
WO2016201301A1 (en) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2017024198A1 (en) 2015-08-06 2017-02-09 The Trustees Of The University Of Pennsylvania Glp-1 and use thereof in compositions for treating metabolic diseases
EP3344650A4 (en) 2015-08-31 2019-04-17 The Trustees Of The University Of Pennsylvania AAV-EPO FOR THE TREATMENT OF PETS
EP3359663A4 (en) 2015-09-24 2019-08-14 The Trustees of The University of Pennsylvania COMPOSITION AND METHOD FOR THE TREATMENT OF A COMPLEMENT-MEDIATED DISEASE
JP7064214B2 (ja) 2015-09-28 2022-05-10 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 抗体回避性ウイルスベクターのための方法および組成物
US11273227B2 (en) 2015-10-09 2022-03-15 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treating Stargardt's disease and other ocular disorders
CA3002980A1 (en) 2015-10-22 2017-04-27 University Of Massachusetts Prostate-targeting adeno-associated virus serotype vectors
EP3364997B1 (en) 2015-10-22 2024-01-17 University of Massachusetts Aspartoacylase gene therapy in the treatment of canavan disease
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
WO2017077451A1 (en) 2015-11-05 2017-05-11 Bamboo Therapeutics, Inc. Modified friedreich ataxia genes and vectors for gene therapy
MA43570A (fr) 2015-12-11 2018-11-14 Univ Pennsylvania Thérapie génique pour traiter l'hypercholestérolémie familiale
JP7061067B2 (ja) 2015-12-14 2022-04-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア クリグラー・ナジャー症候群の処置のための組成物
ES2826384T3 (es) 2015-12-14 2021-05-18 Univ Pennsylvania Terapia génica para trastornos oculares
US11040114B2 (en) 2015-12-24 2021-06-22 Oxyrane Uk Limited Human alpha-N-acetylgalactosaminidase polypeptide
CA3011939A1 (en) 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
WO2017136500A1 (en) 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
HRP20231451T1 (hr) 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
EP4094780A3 (en) 2016-02-12 2023-02-08 University of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
CN109475756A (zh) 2016-02-17 2019-03-15 儿童医疗中心有限公司 Ffa1(gpr40)作为神经血管生成疾病或病症的治疗标靶
AU2017223465A1 (en) 2016-02-22 2018-08-09 The University Of North Carolina At Chapel Hill AAV-IDUA vector for treatment of MPS I-associated blindness
AU2017229347A1 (en) 2016-03-07 2018-11-01 University Of Iowa Research Foundation AAV-mediated expression using a synthetic promoter and enhancer
EP3440210A4 (en) 2016-04-05 2019-11-27 University of Massachusetts COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF EXPRESSION OF GRAINHEAD PROTEIN
EP3443080B1 (en) 2016-04-13 2021-08-11 University of Massachusetts Repairing compound heterozygous recessive mutations by allele exchange
JP7140683B2 (ja) 2016-04-15 2022-09-21 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規なａａｖ８変異カプシド及びそれを含有する組成物
WO2017181105A1 (en) 2016-04-15 2017-10-19 University Of Massachusetts Methods and compositions for treating metabolic imbalance
EP3449250B1 (en) 2016-04-28 2020-11-04 Indiana University Research & Technology Corporation Methods and compositions for resolving components of a virus preparation
JP2019518028A (ja) 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法
US11504435B2 (en) 2016-06-13 2022-11-22 The University Of North Carolina At Chapel Hill Optimized CLN1 genes and expression cassettes and their use
WO2017218852A1 (en) 2016-06-15 2017-12-21 University Of Massachusetts Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
CA2971303A1 (en) 2016-06-21 2017-12-21 Bamboo Therapeutics, Inc. Optimized mini-dystrophin genes and expression cassettes and their use
KR20190096329A (ko) 2016-07-05 2019-08-19 유니버시티 오브 매사추세츠 녹내장에서 신경보호 요법으로서 sfasl의 aav2-매개된 유전자 전달
BR112019000171A2 (pt) 2016-07-08 2019-10-01 Univ Pennsylvania métodos e composições para tratamento de distúrbios e doenças envolvendo rdh12
US11883470B2 (en) 2016-07-25 2024-01-30 The Trustees Of The University Of Pennsylvania Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
KR20190034195A (ko) 2016-07-26 2019-04-01 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 눈에서의 벡터-매개 면역 관용
US10457940B2 (en) 2016-09-22 2019-10-29 University Of Massachusetts AAV treatment of Huntington's disease
AU2017341849B2 (en) 2016-10-13 2024-03-21 University Of Massachusetts AAV capsid designs
BR112019009902A2 (pt) 2016-11-15 2019-08-13 Univ Minnesota método para prevenir ou inibir a deterioração neurocognitiva
SG10201913552UA (en) 2016-12-16 2020-03-30 Alnylam Pharmaceuticals Inc Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
EP3565572A1 (en) 2017-01-07 2019-11-13 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
US11142775B2 (en) 2017-01-13 2021-10-12 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
US11554147B2 (en) 2017-02-20 2023-01-17 The Trustees Of The University Of Pennsylvania Gene therapy for treating familial hypercholesterolemia
CN110573523A (zh) 2017-02-28 2019-12-13 宾夕法尼亚州大学信托人 基于aav载体的流感疫苗
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
JP7455579B2 (ja) 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規アデノ随伴ウイルス（ａａｖ）クレードｆベクター及びその用途
IL268891B1 (en) 2017-03-15 2024-05-01 Univ North Carolina Chapel Hill Polyploid gland associated virus vectors and methods of making and using the same.
CN110709095B (zh) 2017-04-05 2024-05-03 马萨诸塞大学 小基因治疗
JP2020517638A (ja) 2017-04-20 2020-06-18 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法
US11879133B2 (en) 2017-04-24 2024-01-23 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
EP3622073A4 (en) 2017-05-09 2021-01-06 University of Massachusetts METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
RU2019139555A (ru) 2017-05-11 2021-06-11 Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания Генная терапия нейрональных цероидных липофусцинозов
CA3061656A1 (en) 2017-05-17 2018-11-22 The General Hospital Corporation Gene therapy for tuberous sclerosis
CA3098592A1 (en) 2017-05-31 2018-12-06 The Trustees Of The University Of Pennsylvania Gene therapy for treating peroxisomal disorders
EP3638316A4 (en) 2017-06-14 2021-03-24 The Trustees Of The University Of Pennsylvania GENE THERAPY FOR EYE DISORDERS
BR112020000063A2 (pt) 2017-07-06 2020-07-14 The Trustees Of The University Of Pennsylvania terapia gênica mediada por aav9 para tratamento de mucopolissacaridose tipo i
CA3075180A1 (en) * 2017-09-08 2019-03-14 Generation Bio Co. Lipid nanoparticle formulations of non-viral, capsid-free dna vectors
EP3685168A1 (en) 2017-09-20 2020-07-29 The Trustees Of Indiana University Methods for resolving lipoproteins with mass spectrometry
US11739330B2 (en) 2017-09-22 2023-08-29 University Of Massachusetts SOD1 dual expression vectors and uses thereof
EP3694543A1 (en) 2017-10-13 2020-08-19 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
EP3697896A1 (en) 2017-10-16 2020-08-26 Vigeneron GmbH Aav vectors
WO2019089922A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
BR112020008835A2 (pt) 2017-11-07 2020-10-20 The University Of North Carolina At Chapel Hill genes de aga otimizados e cassetes de expressão e seu uso
WO2019100039A1 (en) 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
KR20200096262A (ko) 2017-11-28 2020-08-11 미리머스, 인코포레이티드 RNAi 모델의 유전자 간섭 개발 및 적용 방법
SG11202005618WA (en) 2017-12-19 2020-07-29 Akouos Inc Aav-mediated delivery of therapeutic antibodies to the inner ear
US11008602B2 (en) 2017-12-20 2021-05-18 Roche Molecular Systems, Inc. Non-replicative transduction particles and transduction particle-based reporter systems
WO2019140233A1 (en) 2018-01-12 2019-07-18 The Trustees Of Indiana University Electrostatic linear ion trap design for charge detection mass spectrometry
CA3088323A1 (en) 2018-01-17 2019-07-25 Adrenas Therapeutics, Inc. Adeno-associated virus gene therapy for 21-hydroxylase deficiency
EP3758736B1 (en) 2018-03-02 2024-05-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Il-34 for use in a method of treating retinal inflammation and neurodegeneration
MX2020009579A (es) * 2018-03-15 2020-11-09 Intergalactic Therapeutics Inc Vectores de adn sintetico y metodos de uso.
US20210023241A1 (en) 2018-03-23 2021-01-28 University Of Massachusetts Gene therapeutics for treating bone disorders
CN112533644A (zh) 2018-04-03 2021-03-19 斯特里迪比奥公司 靶向眼组织的病毒载体
EP3774854A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Antibody-evading virus vectors
CN112543766A (zh) 2018-04-03 2021-03-23 斯特里迪比奥公司 抗体逃避性病毒载体
CA3098448A1 (en) 2018-04-27 2019-10-31 University Of Massachusetts Aav capsids identified by in vivo library selection
CA3098871A1 (en) 2018-05-08 2019-11-14 Rutgers, The State University Of New Jersey Aav-compatible laminin-linker polymerization proteins
WO2019236143A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Apparatus and method for calibrating or resetting a charge detector
AU2019281255B2 (en) 2018-06-04 2023-01-12 The Trustees Of Indiana University Ion trap array for high throughput charge detection mass spectrometry
WO2019236139A1 (en) 2018-06-04 2019-12-12 The Trustees Of Indiana University Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
EP4376051A2 (en) 2018-06-04 2024-05-29 The Trustees of Indiana University Charge detection mass spectrometry with real time analysis and signal optimization
KR20210035101A (ko) 2018-06-04 2021-03-31 더 트러스티즈 오브 인디애나 유니버시티 정전기 선형 이온 트랩에서 이온을 포획하기 위한 장치 및 방법
EP3810782A2 (en) 2018-06-22 2021-04-28 Asklepios Biopharmaceutical, Inc. Vectors for gene delivery that persist within cells
US20210269829A1 (en) 2018-06-28 2021-09-02 The University Of North Carolina At Chapel Hill Optimized cln5 genes and expression cassettes and their use
BR112021000763A2 (pt) 2018-07-16 2021-04-13 Selecta Biosciences, Inc. Métodos e composições de construtos e vetores de otc
MX2021000638A (es) 2018-07-16 2021-06-23 Selecta Biosciences Inc Métodos y composiciones de construcciones y vectores de acidemia metilmalónica.
WO2020033833A1 (en) 2018-08-10 2020-02-13 The University Of North Carolina At Chapel Hill Optimized cln7 genes and expression cassettes and their use
TW202020157A (zh) 2018-08-16 2020-06-01 美商艾爾妮蘭製藥公司 用於抑制lect2基因表現之組合物及方法
AU2019384065A1 (en) 2018-11-20 2021-06-03 The Trustees Of Indiana University Orbitrap for single particle mass spectrometry
CN113166760A (zh) 2018-11-23 2021-07-23 赛诺菲 用于抑制angptl8的新型rna组合物和方法
WO2020112967A1 (en) 2018-11-29 2020-06-04 University Of Massachusetts Modulation of sptlc1 via recombinant adeno-associated vectors
CA3118567A1 (en) 2018-12-03 2020-06-11 The Trustees Of Indiana University Apparatus and method for simultaneously analyzing multiple ions with an electrostatic linear ion trap
SG11202106356QA (en) 2018-12-20 2021-07-29 Vigeneron Gmbh An optimized acceptor splice site module for biological and biotechnological applications
WO2020136154A1 (en) 2018-12-27 2020-07-02 F. Hoffmann-La Roche Ag Non-replicative transduction particles and transduction particle-based reporter systems for detection of acinetobacter baumannii
US20220089670A1 (en) 2018-12-28 2022-03-24 University Of Rochester Gene Therapy for BEST1 Dominant Mutations
US11572595B2 (en) 2018-12-31 2023-02-07 Roche Molecular Systems, Inc. Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
CA3131023A1 (en) 2019-02-22 2020-08-27 Michael R. Volkert Oxr1 gene therapy
EA202192501A1 (ru) 2019-03-21 2021-12-16 Страйдбайо, Инк. Рекомбинантные аденоассоциированные вирусные векторы
SG11202111353QA (en) 2019-04-15 2021-11-29 Univ Iowa Res Found Methods and compositions for transgene expression
EP3955971A1 (en) 2019-04-15 2022-02-23 University of Iowa Research Foundation Compositions and methods for treatment of cystic fibrosis
JP2022531095A (ja) 2019-04-17 2022-07-06 コディアック バイオサイエンシーズ， インコーポレイテッド エキソソーム及びａａｖの組成物
EP3956474A1 (en) 2019-04-18 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and prognosis of cancer
WO2020219527A1 (en) 2019-04-23 2020-10-29 The Trustees Of Indiana University Identification of sample subspecies based on particle charge behavior under structural change-inducing sample conditions
KR20220004121A (ko) 2019-04-28 2022-01-11 셀렉타 바이오사이언시즈, 인크. 바이러스 전달 벡터에 대한 기존의 면역을 갖는 대상체의 치료 방법
AU2020284555A1 (en) 2019-05-28 2021-12-23 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
CA3144864A1 (en) 2019-06-27 2020-12-30 Pfizer Inc. Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
CA3145662A1 (en) 2019-07-02 2021-01-07 M6P Therapeutics Vector compositions and methods of using same for treatment of lysosomal storage disorders
US20220396806A1 (en) 2019-07-26 2022-12-15 Akouos, Inc. Methods of treating hearing loss using a secreted target protein
EP4022061A1 (en) 2019-08-27 2022-07-06 Sanofi Compositions and methods for inhibiting pcsk9
BR112022003860A2 (pt) 2019-09-03 2022-08-16 Alnylam Pharmaceuticals Inc Composições e métodos para inibir a expressão do gene lect2
CN114555814A (zh) 2019-09-13 2022-05-27 罗特格斯新泽西州立大学 Aav相容的层粘连蛋白-连接子聚合蛋白
JP2022549138A (ja) 2019-09-18 2022-11-24 インターガラクティック セラピューティクス インコーポレイテッド 合成ｄｎａベクターおよびその使用法
WO2021062012A1 (en) 2019-09-25 2021-04-01 Emory University Use of klk10 and engineered derivatizations thereof
US11834659B2 (en) 2019-09-26 2023-12-05 Massachusetts Institute Of Technology Trans-activated functional RNA by strand displacement and uses thereof
WO2021062096A1 (en) 2019-09-26 2021-04-01 Massachusetts Institute Of Technology Microrna-based logic gates and uses thereof
EP4038189A1 (en) 2019-10-04 2022-08-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
WO2021072115A1 (en) 2019-10-08 2021-04-15 Regents Of The University Of Minnesota Crispr-mediated human genome editing with vectors
WO2021076656A1 (en) 2019-10-15 2021-04-22 University Of Massachusetts Rna editor-enhanced rna trans-splicing
WO2021076925A1 (en) 2019-10-17 2021-04-22 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
WO2021087325A1 (en) 2019-11-01 2021-05-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
TW202132568A (zh) 2019-11-13 2021-09-01 美商阿尼拉製藥公司 用於治療血管收縮素原相關病症之方法及組成物
WO2021119053A1 (en) 2019-12-10 2021-06-17 Shire Human Genetic Therapies, Inc. Adeno associated virus vectors for the treatment of hunter disease
US20220356537A1 (en) 2019-12-31 2022-11-10 Roche Molecular Systems, Inc. Quantitative pcr screening of inducible prophage from bacterial isolates
EP4090381A1 (en) 2020-01-17 2022-11-23 The United States of America, as represented by the Secretary, Department of Health and Human Services <smallcaps/>? ? ?crx-? ? ? ? ?gene therapy for treatment ofautosomal dominant retinopathies
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
IL295445A (en) 2020-02-10 2022-10-01 Alnylam Pharmaceuticals Inc Preparations and methods for silencing vegf-a expression
US20230190785A1 (en) 2020-03-30 2023-06-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
BR112022019304A2 (pt) 2020-03-31 2022-12-06 Univ Massachusetts Variantes de capsídeo de aav e usos das mesmas
CN117377763A (zh) 2020-04-06 2024-01-09 阿尔尼拉姆医药品有限公司 用于沉默myoc表达的组合物和方法
AU2021251754A1 (en) 2020-04-07 2022-11-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing SCN9A expression
US20230257771A1 (en) 2020-04-20 2023-08-17 Christiana Care Health Services, Inc. Aav delivery system for lung cancer treatment
WO2021231538A2 (en) 2020-05-13 2021-11-18 Akouos, Inc. Compositions and methods for treating kcnq4-associated hearing loss
JP2023526047A (ja) 2020-05-13 2023-06-20 アコーオス インコーポレイテッド Ｓｌｃ２６ａ４関連難聴を治療するための組成物及び方法
WO2021237097A1 (en) 2020-05-21 2021-11-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
WO2022006253A2 (en) 2020-06-30 2022-01-06 University Of Iowa Research Foundation Methods and compositions for administering recombinant viral vectors
WO2022011099A1 (en) 2020-07-08 2022-01-13 Regents Of The University Of Minnesota Modified hexosaminidase and uses thereof
AU2021325954A1 (en) 2020-08-14 2023-03-02 The Trustees Of The University Of Pennsylvania Novel AAV capsids and compositions containing same
EP4200429A1 (en) 2020-08-24 2023-06-28 The Trustees of The University of Pennsylvania Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
WO2022047201A1 (en) 2020-08-27 2022-03-03 University Of Iowa Research Foundation Gene knock-out for treatment of glaucoma
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
JP2023540960A (ja) 2020-09-10 2023-09-27 ルートビヒ－マキシミリアンズ－ウニベルジテート ミュンヘン 操作されたａａｖベクター
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達
KR20230083287A (ko) 2020-10-07 2023-06-09 리젠엑스바이오 인크. Cln2 질환의 안구 징후에 대한 유전자 요법
JP2023545502A (ja) 2020-10-16 2023-10-30 サノフイ リポタンパク質（ａ）を阻害するためのｒｎａ組成物および方法
US20230383294A1 (en) 2020-10-16 2023-11-30 Sanofi Novel rna compositions and methods for inhibiting angptl3
WO2022087041A1 (en) 2020-10-21 2022-04-28 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
JP2023550581A (ja) 2020-10-29 2023-12-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ａａｖカプシド及びそれを含有する組成物
TW202237150A (zh) 2020-12-01 2022-10-01 美商艾拉倫製藥股份有限公司 用於抑制ｈａｏ１（羥基酸氧化酶１（乙醇酸氧化酶））基因表現的方法及組成物
EP4255570A1 (en) 2020-12-01 2023-10-11 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
EP4255457A1 (en) 2020-12-03 2023-10-11 University of Massachusetts Development of novel gene therapeutics for fibrodysplasia ossificans progressiva
WO2022146839A1 (en) 2020-12-29 2022-07-07 Akouos, Inc. Compositions and methods for treating clrn1-associated hearing loss and/or vision loss
WO2022150335A1 (en) 2021-01-05 2022-07-14 Selecta Biosciences, Inc. Viral vector dosing protocols
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
JP2024505257A (ja) 2021-02-01 2024-02-05 レジェンクスバイオ インコーポレーテッド 神経セロイドリポフスチン症の遺伝子治療
EP4288556A1 (en) 2021-02-05 2023-12-13 Regents of the University of Minnesota Methods for preventing cardiac or skeletal defects in diseases including mucopolysaccharidoses
JP2024509792A (ja) 2021-02-26 2024-03-05 武田薬品工業株式会社 ファブリー病の治療のための組成物及び方法
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
CN113549642B (zh) * 2021-03-02 2023-03-07 体必康生物科技(广东)股份有限公司 一种结核分枝杆菌整合型表达质粒及其应用
WO2022198038A1 (en) 2021-03-19 2022-09-22 Adrenas Therapeutics, Inc. Gene therapies for 21-hydroxylase deficiency
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
JP2024511851A (ja) 2021-03-30 2024-03-15 エーエーブイネルジーン インク． 改変血漿凝固第ｖｉｉｉ因子およびその使用方法
US20240115738A1 (en) 2021-04-15 2024-04-11 Spirovant Sciences, Inc. Methods and compositions for treatment of cystic fibrosis
WO2022221529A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
CA3216146A1 (en) 2021-04-23 2022-10-27 Douglas Anderson Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
AR125467A1 (es) 2021-04-27 2023-07-19 Univ Pennsylvania Cápsides de virus adenoasociados derivados de porcinos y usos de los estos
EP4351592A1 (en) 2021-06-09 2024-04-17 Universität Duisburg-Essen Method for immortalising vesicle-secreting cells
WO2022266113A1 (en) 2021-06-14 2022-12-22 Bridgebio Gene Therapy Research, Inc. Gene therapy for tuberous sclerosis
EP4363580A1 (en) 2021-06-30 2024-05-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
WO2023279108A1 (en) 2021-07-01 2023-01-05 Bridgebio Gene Therapy Research, Inc. Gene therapy for galactosemia
WO2023004370A1 (en) 2021-07-21 2023-01-26 Aspen Neuroscience, Inc. Aav-based modulation of gba1 and related compositions and uses thereof
IL311572A (en) 2021-09-30 2024-05-01 Akouos Inc Compositions and methods for treating KCNQ4-related hearing loss
CA3235145A1 (en) 2021-10-12 2023-04-20 Bridgebio Gene Therapy Llc Methods and compositions for treating leukodystrophies
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
CA3235269A1 (en) 2021-10-12 2023-04-20 Cartesian Therapeutics, Inc. Viral vector dosing protocols
CA3237037A1 (en) 2021-11-14 2023-05-19 Cartesian Therapeutics, Inc. Multiple dosing with viral vectors
WO2023102442A1 (en) 2021-11-30 2023-06-08 Jaguar Gene Therapy, Llc Gene therapy methods for treatment of diabetes
WO2023114816A1 (en) 2021-12-14 2023-06-22 Neurogene, Inc. Recombinant optimized galc constructs and methods for treating galc-associated disorders
WO2023129940A1 (en) 2021-12-30 2023-07-06 Regel Therapeutics, Inc. Compositions for modulating expression of sodium voltage-gated channel alpha subunit 1 and uses thereof
WO2023147383A1 (en) 2022-01-25 2023-08-03 Bridgebio Services Inc. Gene therapy for genetic hearing loss
GB202201242D0 (en) 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
TW202342525A (zh) 2022-02-02 2023-11-01 美商阿科奧斯公司 用於治療前庭神經鞘瘤相關症狀之抗ｖｅｇｆ抗體構築體及相關方法
WO2023150687A1 (en) 2022-02-04 2023-08-10 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors, and methods of use thereof
WO2023164636A1 (en) 2022-02-25 2023-08-31 Vor Biopharma Inc. Compositions and methods for homology-directed repair gene modification
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023187728A1 (en) 2022-04-01 2023-10-05 Takeda Pharmaceutical Company Limited Gene therapy for diseases with cns manifestations
GB202206336D0 (en) 2022-04-29 2022-06-15 Univ Edinburgh Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
WO2023250362A1 (en) 2022-06-21 2023-12-28 Regel Therapeutics, Inc. Genetic regulatory elements and uses thereof
WO2024015966A2 (en) 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
WO2024036324A1 (en) 2022-08-11 2024-02-15 Selecta Biosciences, Inc. Compositions and methods related to immunoglobulin proteases and fusions thereof
WO2024047587A1 (en) 2022-08-31 2024-03-07 Regel Therapeutics, Inc. Cas-phi compositions and methods of use
WO2024086747A1 (en) 2022-10-19 2024-04-25 Affinia Therapeutics Inc. Recombinant aavs with improved tropism and specificity
WO2024092171A1 (en) 2022-10-26 2024-05-02 University Of Iowa Research Foundation Method to deliver large genes using virus and a dna recombination system
WO2024098061A2 (en) 2022-11-04 2024-05-10 Genkardia Inc. Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
WO2024105638A1 (en) 2022-11-18 2024-05-23 Jcr Pharmaceuticals Co., Ltd. Recombinant aav vectors and methods for treatment of hunter syndrome
WO2024108217A1 (en) 2022-11-18 2024-05-23 Genkardia Inc. Methods and compositions for preventing, treating, or reversing cardiac diastolic dysfunction

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
AU7906691A (en) * 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors

Also Published As

Publication number Publication date
JPH08504102A (ja) 1996-05-07
IL107862A0 (en) 1994-04-12
KR100256890B1 (ko) 2000-05-15
US5478745A (en) 1995-12-26
EP0673415A1 (en) 1995-09-27
EP0673415B1 (en) 2009-02-18
DE69334262D1 (de) 2009-04-02
EP0673415A4 (en) 1997-05-21
ATE423203T1 (de) 2009-03-15
JP4117023B2 (ja) 2008-07-09
WO1994013788A1 (en) 1994-06-23

Similar Documents

Publication Publication Date Title
TW260708B (zh)
ZA963863B (en) Recombinant viral vector system.
EP1312679B8 (en) Recombinant MVA virus, and the use thereof
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
EP0319570A4 (en) Recombinant human cytomegalovirus containing foreign gene and use thereof
GB9618477D0 (en) Gene therapy
NO964874L (no) Fusjonsglykoprotein fra HCMV og HSV
HUP9802587A2 (hu) Glükózzal indukálható rekombináns virális vektor, ezt tartalmazó gyógyszerkészítmény és ezzel transzformált sejtek
FR2724320B1 (fr) Nouvel implant pour le traitement des maladies acquises
CA2184297A1 (fr) Virus recombinants codant pour une activite glutamate decarboxylase (gad)
FR2720756B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
MY119381A (en) Recombinant mva virus, and the use thereof